The UK-based company was spun out of University College London and launched in October 2022 with funding from UCL Technology Fund.

Bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs, with the US FDA granting Rare Pediatric Disease designation (RPDD) in July 2023 for BGT-OTCD, the company’s investigational liver-targeted gene therapy for the treatment of Ornithine transcarbamylase deficiency (OTCD).